PTHS (Pelthos Therapeutics) FCF Margin %: -122.13% (As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $29.03
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics FCF Margin %?

Pelthos Therapeutics PTHS -0.62% 8 FCF Margin % is -122.13% as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 958 Biotechnology companies, Pelthos Therapeutics ranks worse than 55.95% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Pelthos Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-13.32 Mil. Pelthos Therapeutics's Revenue for the three months ended in Mar. 2026 was $10.91 Mil. Therefore, Pelthos Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -122.13%.

As of today, Pelthos Therapeutics's current FCF Yield % is -34.96%.

The historical rank and industry rank for Pelthos Therapeutics's FCF Margin % or its related term are showing as below:

PTHS' s FCF Margin % Range Over the Past 10 Years
Min: -1813   Med: -997.56   Max: -127.35
Current: -127.35

During the past 6 years, the highest FCF Margin % of Pelthos Therapeutics was -127.35%. The lowest was -1813.00%. And the median was -997.56%.

PTHS's FCF Margin % is ranked worse than
55.95% of 958 companies
in the Biotechnology industry
Industry Median: -85.21 vs PTHS: -127.35

Pelthos Therapeutics FCF Margin % Related Terms

Pelthos Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics FCF Margin % Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -182.12

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -206.04 -66.59 -122.13

PTHS vs CGTX, BDTX, CBUS: FCF Margin % Comparison

For the Biotechnology subindustry, Pelthos Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pelthos Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pelthos Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Pelthos Therapeutics's FCF Margin % falls into.


PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Pelthos Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-30.587/16.795
=-182.12 %

Pelthos Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-13.32/10.906
=-122.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -122.13% mean?
Pelthos Therapeutics (PTHS) has a FCF Margin % of -122.13% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pelthos Therapeutics and its competitors. According to the industry distribution chart, Pelthos Therapeutics ranks #536 out of 958 companies in the Biotechnology industry, placing it in the top 55.9%.
Is Pelthos Therapeutics' FCF Margin % too high?
Pelthos Therapeutics' current FCF Margin % is -122.13%. Based on the distribution chart, Pelthos Therapeutics ranks #536 out of 958 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' FCF Margin % compare to CGTX and BDTX?
According to the Biotechnology industry distribution chart, Pelthos Therapeutics ranks #536 out of 958 companies for FCF Margin %. This places Pelthos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current FCF Margin % is -122.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current FCF Margin % of -122.13%. The current FCF Margin % is -122.13%. Pelthos Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current FCF Margin % is -122.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.03
Price